Tianshu Pharmaceutical, Manufacturing Base of Nanjing Vcare, Has Its Near-term GHG Emission Reduction Targets Validated by SBTi

2025-12-20

　　Recently, the near-term greenhouse gas (GHG) emission reduction targets of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), the production base affiliated with Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare), have been successfully validated by the Science Based Targets initiative (SBTi). This fully demonstrates Tianshu Pharmaceutical’s determination and confidence in actively responding to climate change and firmly practicing the ESG philosophy, marking a solid step forward for the company on the path of low-carbon and sustainable development.

 

　　Validated by SBTi, Tianshu Pharmaceutical commits to cutting Scope 1 and Scope 2 GHG emissions by 63% by 2035 against the 2024 baseline year, and will continuously monitor and reduce its Scope 3 emissions.

 

　　SBTi is a global joint initiative launched by the United Nations Global Compact (UNGC), Carbon Disclosure Project (CDP), World Resources Institute (WRI) and World Wildlife Fund (WWF). It aims to help enterprises set science-aligned emission reduction targets to tackle climate change. Founded in 2015, SBTi has grown into one of the world’s most influential corporate climate action standard systems, providing enterprises with scientific and systematic emission reduction methodologies and supporting their transition to low-carbon development.

 

　　Tianshu Pharmaceutical has deeply integrated the ESG philosophy into its corporate strategy and operations. The company actively implements process optimization, technological innovation, facility and equipment upgrading, and establishes an energy monitoring system to realize real-time feedback on electricity, water and other energy consumption of individual buildings. By advocating green office practices, energy conservation and carbon reduction have been embedded into daily operations. Furthermore, Tianshu Pharmaceutical extends the sustainable development concept to supply chain management, reducing absolute GHG emissions generated from purchased goods and services, and joins hands with partners to drive low-carbon development across the supply chain.

 

　　Upholding its commitment to sustainable development, Tianshu Pharmaceutical will systematically advance ESG development and explore green development pathways in the pharmaceutical industry. While empowering drug R&D and safeguarding human health, the company actively addresses climate challenges and delivers continuous positive social and environmental impacts. Up to now, thanks to its solid practices in environmental protection, Tianshu Pharmaceutical has been honored with titles such as Hubei Provincial Green Factory and Hubei Environmental Green Label Enterprise.

Prev

Only Three in Nanjing! Nanjing Vcare’s Full-industry-chain Pilot Platform for Drug R&D Shortlisted in the 2025 Provincial Manufacturing Pilot Platform Proposed Upgrading List

Next

Nanjing Vcare's Manufacturing Base Tianshu Pharmaceutical Obtains Marketing Approval for Vonoprazan Fumarate API